Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Hannah Parris

Virginia Borges, MD, MMSc

This study plans to learn more about the immune system's response to breast cancer in young women.

The investigators will be looking at the level of immune suppression in different types of breast cancer. The investigators will use blood, urine, and tissue samples from patients with Pregnancy Associated Breast Cancer (PABC) versus non-PABC, as well as comparing different types of breast cancer. If tissue sampling permits, the investigators may use some of the breast cancer tissue to develop models for human cancer for drug targeting. Understanding the immune response and suppression in different types of cancer will help us understand mechanisms involved in breast cancer better and help the investigators in developing new treatment in the future.

Tissue, Blood and urine may be collected from subjects who were recently diagnosed. Subjects who were diagnosed after treatment begins or has ended will only be eligible for tissue donation section of study

The study is restricted by gender due to the population of interest being women with pregnancy associated breast cancer and appropriately matched age controls.

The Immune System's Response to Young Women's Breast Cancer

A Translational Study of the Interactions Between Prior Pregnancy and the Biologic Subtype of Breast Cancer in Defining the Cancer: Host Immunologic Interaction

University of Colorado, Denver

Study Project Manager

Start-Up Unit Manager

Study Director

An ambispective observational registry study of pregnancy and breast cancer

A multicenter, observational, non-post-marketing (non-PMS), ambispective (retrospective and prospective from the registry opening) study which will enroll patients with breast cancer in any of these three situations:

1. Patients with gestational breast cancer, defined as breast cancer diagnosed during pregnancy, breastfeeding or up to a year after delivery.
2. Patients who become pregnant after a breast cancer diagnosis.
3. Patients with breast cancer who have followed any fertility preservation technique prior to the start of breast cancer treatment.

It is estimated a minimum recruitment period of approximately 3 years from the study activation. The study will remain open as long as possible in order to collect as much information as possible. GEICAM will actively search for funding for this.

Patients may also be concurrently enrolled in an interventional clinical trial. This observational registry study of pregnancy and breast cancer that collects significant data obtained from standard clinical practice, regarding the clinical characteristics of patients with breast cancer in any of the three situations described above. These data will allow the performance of both descriptive and exploratory analyses in order to evaluate the associations between different breast cancer subtypes and risk factors observed.

Finally, this study will collect high quality molecular data derived from the analysis of biological samples (paraffin-embedded tumor and peripheral blood samples) to reach a better understanding of the biological mechanisms involved in breast cancer in relation to pregnancy.

No treatment regimen will be protocol specified. This is an observational study in which clinical decisions concerning the optimum management strategy for a particular patient are taken independently of and/or prior to, any decision by the physician to invite a patient to participate in the study. The treating physician will make all treatment decisions according to his/her regular clinical practice independent of this study.

A whole blood sample will be collected from all patients enrolled preferably at the enrollment visit (after signing the ICF).

Registry Study of Pregnancy and Breast Cancer

An Ambispective Observational Registry Study of Pregnancy and Breast Cancer

Data for this study will be recorded into the electronic case report form (eCRF) via web using Remote Data Capture (RDC) from Oracle Clinical®. Once patient has signed the ICF or verified that the data of deceased patients can be included, designated site personnel will complete the register of each patient in the eCRF, where an identification number will automatically be assigned.

Data will be recorded in the eCRF at the time of patient enrollment and approximately every year.

Data for this study will be recorded into the eCRF via web using RDC (Remote Data Capture) from Oracle Clinical®. Once patient has signed the ICF or verified that the data of deceased patients can be included, designated site personnel will complete the register of each patient in the eCRF, where an identification number will automatically be assigned.

Data will be recorded in the eCRF at the time of patient enrollment and approximately every year.

Assess the clinicopathological characteristics of cancer in the patients enrolled in the study. For this, it is used the Tumor, Node, Metastasis (TNM) staging system is the most common way that doctors stage breast cancer. Patient scans and tests give some information about the stage of the cancer.

Tumor (T) size describes the size of the tumour. Larger T is associated with inferior survival.

Tumor cannot be assessed (TX): can't be assessed. Tis: ductal carcinoma in situ. T1: tumour is 2 centimetres (cm) across or less. T1mi: tumour is 0.1cm across or less T1a: tumour \>0.1 cm but \<0.5 cm T1b: tumour \>0.5 cm but \<1 cm T1c: tumour \>1 cm but \<2 cm T2: tumour \>2 cm but \<5 cm across. T3: tumour \>5 cm across. T4a: tumour has spread into the chest wall T4b: tumour has spread into the skin and the breast might be swollen T4c: tumour has spread to both the skin and the chest wall T4d: inflammatory carcinoma

Assess the clinicopathological characteristics of cancer in the patients enrolled in the study. For this, it is used the Tumor, Node, Metastasis (TNM) staging system is the most common way that doctors stage breast cancer. Patient scans and tests give some information about the stage of the cancer.

Lymph Node (N) conditions describes whether the cancer has spread to the Lymph Nodes (LN). Prognosis is better when cancer has not spread to the LN. The more LN that contain cancer, the poorer prognosis tends to be.

Node cannot be assessed (NX): LN can't be assessed N0: no Cancer Cells (CC) N1: CC in the LN in the armpit but the nodes are not stuck to surrounding tissues.

N2a: CC in the LN in the armpit, which are stuck to each other and to other structures.

N2b: CC in the LN behind the breast bone. N3a: CC in LN below the collarbone. N3b: CC in LN in the armpit and behind the breastbone. N3c: CC in LN above the collarbone.

Assess the clinicopathological characteristics of cancer in the patients enrolled in the study. For this, it is used the Tumor, Node, Metastasis (TNM) staging system is the most common way that doctors stage breast cancer. Patient scans and tests give some information about the stage of the cancer.

Metastasis (M) describes whether the cancer has spread to a different part of the body.

M0 means that there is no sign that the cancer has spread. cMo(i+) means there is no sign of the cancer on physical examination, scans or x-rays. But cancer cells are present in blood, bone marrow, or lymph nodes far away from the breast cancer - the cells are found by laboratory tests M1 means the cancer has spread to another part of the body.

Cancer cells are given a Grade (G) when they are removed from the breast and checked under a microscope. The G is based on how much the cancer cells look like normal cells.

G1 or well differentiated (score 3, 4, or 5): cells are slower-growing, and look more like normal breast tissue.

G2 or moderately differentiated (score 6, 7): cells are growing at a speed of and look like cells somewhere between G1 and 3.

G3 or poorly differentiated (score 8, 9): cells look very different from normal and will probably grow and spread faster.

The histopathological differentiation is analyzed on tumor samples. The collection of a sample of the primary archival tumor and/or a sample of metastatic lesions will be requested, when available.

Receptors (R) are proteins in or on cells that can attach to certain substances in the blood. Normal breast cells and some breast cancer cells have R that attach to the hormones estrogen and progesterone, and depend on these hormones to grow.

Breast cancer cells may have one, both, or none of these R:

* Estrogen Receptors (ER) -positive: are called ER-positive (or ER+) cancers.
* Progesterone Receptors (PR) -positive: are called PR-positive (or PR+) cancers.
* Hormone receptor (HR) -positive: If the cancer cell has one or both of the R above, the term hormone-receptive positive (also called hormone-positive or HR+) breast cancer may be used.
* HR-negative: If the cancer cell has neither the ER nor the PR, it's called hormone-receptor negative (also called hormone-negative or HR-).

The hormonal R status is analyzed on tumor samples. The collection of a sample of the primary archival tumor and/or a sample of metastatic lesions will be requested, when available.

HER2 is a growth-promoting protein on the outside of all breast cells. Cells with higher than normal levels of HER2 are called HER2+. These cancers tend to grow and spread faster than other breast cancers, but are much more likely to respond to treatment with drugs that target the HER2 protein.

A biopsy or surgery sample of the cancer is tested with either immunohistochemical stains (IHC) or Fluorescent in situ hybridization (FISH).

* IHC result 0 or 1+: cancer is considered HER2-negative. These cancers do not respond to treatment with drugs that target HER2.
* IHC result is 3+: the cancer is HER2-positive. These cancers are usually treated with drugs that target HER2.
* IHC result is 2+: HER2 status of the tumor is not clear and is called "equivocal." HER2 status needs to be tested with FISH to clarify the result.

HER2 is analyzed on tumor samples. The collection of a sample of the primary archival tumor and/or a sample of metastatic lesions will be requested, when available.

Ki-67 is a protein in cells that increases as they prepare to divide into new cells. A staining process can measure the percentage of tumor cells that are positive for Ki-67. The more positive cells there are, the more quickly they are dividing and forming new cells. In breast cancer, a result of less than 10% is considered low, 10-20% borderline, and high if more than 20%.

Ki-67 is analyzed on tumor samples. The collection of a sample of the primary archival tumor and/or a sample of metastatic lesions will be requested, when available.

BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged DNA and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to cancer.

People who have inherited mutations in BRCA1 and BRCA2 tend to develop breast and ovarian cancers at younger ages than people who do not have these mutations.

BRCA1 and 2 mutations are analyzed on whole blood samples, that are preferably collected at the enrolment visit (after signing the informed consent).

Disease-free survival (DFS): It is defined as the time from date of initial breast cancer surgery to the date of the first documented relapse event (local, regional and/or distant) of the disease, second breast or non-breast primary tumor, or death due to any cause, whichever occurs first. In the event that none of the previous events were observed, censoring the last contact date will be considered.

Event-free survival (EFS): It is defined as the time from date of breast cancer diagnosis to the date of the first documented event of disease progression which excludes the potentially curative surgery, relapse (local, regional and/or distant) of the disease after the curative surgery, second breast or non-breast primary tumor, or death due to any cause, whichever occurs first. In the event that none of the previous events were observed, censoring the last contact date will be considered.

Progression-free survival (PFS): It is defined as the time from the start date of a specific treatment to the documentation of disease progression on such treatment, or death due to any cause, whichever occurs first. In the event that none of the previous events were observed, censoring the last contact date will be considered.

Overall survival (OS): It is defined as the time from date of initial breast cancer diagnosis to the date of death due to any cause.

Number of patients with breast cancer managed to get pregnant, spontaneously or through in vitro fertilization (IVF) methods, considering both the patients with early disease and the patients with advanced disease.

Regarding the live-born children, serious diseases and age until the progression is known.

Study title	NCT ID	Conditions	Eligibility	Organization
The Immune System's Response to Young Women's Breast Cancer	NCT01503190	Breast Cancer Breast Cancer a...	18 Years -	University of Colorado, Denver
The Immune System's Response to Young Women's Breast Cancer	NCT01503190	Breast Cancer Breast Cancer a...	18 Years -	University of Colorado, Denver
Registry Study of Pregnancy and Breast Cancer	NCT04603820	Breast Cancer a...	18 Years -	Spanish Breast Cancer Research Group
Registry Study of Pregnancy and Breast Cancer	NCT04603820	Breast Cancer a...	18 Years -	Spanish Breast Cancer Research Group

Spots Global Cancer Trial Database for breast cancer and pregnancy